This trialstudies a new drug to treat advanced cancers and a type of lymphoma.
- Non-Hodgkin Lymphoma
- Advanced Solid Tumors
- Solid Metastatic Tumor
3 Primary · 7 Secondary · Reporting Duration: One year after last patient first dose
1 Treatment Group
1 of 1
482 Total Participants · 1 Treatment Group
Primary Treatment: ATG-101 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many individuals are being included in this medical trial?
"Indeed, the research hosted on clinicaltrials.gov indicates that this trial is actively recruiting patients at 4 different sites with a total of 482 participants needed. This study was first posted around December 15th 2021 and most recently edited in November 14th 2022." - Anonymous Online Contributor
What is the desired outcome of this clinical evaluation?
"As reported by the trial sponsor, Antengene Biologics Limited, this study's primary outcome will be Dose Limiting Toxicity (DLT) and it is to be measured over a one-year period. Additionally, secondary objectives include Disease Control Rate (DCR), Overall Response Rate(ORR), as well as pharmacokinetic evaluation of ATG-101 serum concentrations." - Anonymous Online Contributor
Is the research team actively seeking additional participants?
"Indeed, the data hosted on clinicaltrials.gov attests that this experimental treatment is actively recruiting patients. This trial was initially published on December 15th 2021 and has since been updated on November 14th 2022. There are 482 vacancies across 4 separate medical centres." - Anonymous Online Contributor
Are there any serious risks associated with the use of ATG-101?
"The safety of ATG-101 is estimated to be a 1 as this trial has only completed the first stage, which limits available evidence on efficacy and safety." - Anonymous Online Contributor
In what geographic regions is this scientific inquiry being conducted?
"This research is being conducted at the University of Colorado Hospital in Boulder, Fox Chase Cancer Center located in Philadephia and the esteemed University of California San Francisco. Additionally, there are 4 other locations involved with this study." - Anonymous Online Contributor